What is the 13F Pro Quality Score for VYNE?

13F Pro ranks VYNE Therapeutics Inc. (VYNE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VYNE's current score at https://13fpro.ai/research/VYNE (free sign-up required for the full ranking).

Where does 13F Pro source VYNE data?

All VYNE Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. VYNE Therapeutics Inc. files with the SEC under CIK 1566044. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VYNE in?

VYNE Therapeutics Inc. (VYNE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VYNE research updated on 13F Pro?

VYNE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

VYNE Therapeutics Inc.(VYNE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1566044 VYNE stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $21.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

VYNE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for VYNE Therapeutics Inc. (VYNE), a Healthcare sector company. VYNE is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $21.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), VYNE Therapeutics Inc. reports quarterly revenue of $86.0K, net income of $-3.6M, free cash flow of $-4.1M. Top institutional holders of VYNE by reported 13-F value include Nantahala Capital Management,, Lynx1 Capital Management, Shay Capital, based on the most recent SEC filings. VYNE trades on the Nasdaq exchange and files with the SEC under CIK 1566044. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VYNE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VYNE Therapeutics Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$86.0K

Net Income

Q1 2026

$-3.6M

Free Cash Flow

Q1 2026

$-4.1M

D/E Ratio

Q1 2026

0.00

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-11.1% YoY

$424.0KFY 2023

FY18 $0.00FY20 $21.0MFY22 $477.0KFY23 $424.0K

Net Income

-22.6% YoY

$-28.5MFY 2023

FY18 $-74.2MFY20 $-255.6MFY22 $-23.2MFY23 $-28.5M

Operating Income

+14.7% YoY

$-29.3MFY 2023

FY18 $-74.9MFY20 $-252.5MFY22 $-34.3MFY23 $-29.3M

EPS (Diluted)

+61.8% YoY

$-2.78FY 2023

FY18 —FY20 $7.88FY22 $-7.28FY23 $-2.78

Total Assets

+139.7% YoY

$97.7MFY 2023

FY18 $139.9MFY20 $93.7MFY22 $40.8MFY23 $97.7M

Total Debt

$0.00FY 2023

FY18 —FY20 $33.2MFY22 $0.00FY23 $0.00

Op. Cash Flow

+13.2% YoY

$-25.3MFY 2023

FY18 $-68.7MFY20 $-137.1MFY22 $-29.2MFY23 $-25.3M

Metric	FY 2023	FY 2022	FY 2020	FY 2018	FY 2017	FY 2016
Revenue	$424.0K -11.1%	$477.0K -97.7%	$21.0M	$0.00 -100.0%	$4.6M +579.8%	$674.0K
Net Income	$-28.5M -22.6%	$-23.2M +90.9%	$-255.6M -244.6%	$-74.2M -155.1%	$-29.1M -106.7%	$-14.1M
Operating Income	$-29.3M +14.7%	$-34.3M +86.4%	$-252.5M -237.2%	$-74.9M -153.1%	$-29.6M -106.5%	$-14.3M
EPS (Diluted)	$-2.78 +61.8%	$-7.28 -192.4%	$7.88	—	—	—
Total Assets	$97.7M +139.7%	$40.8M -56.5%	$93.7M -33.0%	$139.9M +109.3%	$66.9M +59.0%	$42.1M
Total Debt	$0.00	$0.00 -100.0%	$33.2M	—	—	—
Operating Cash Flow	$-25.3M +13.2%	$-29.2M +78.7%	$-137.1M -99.6%	$-68.7M -143.3%	$-28.2M -1146.0%	$-2.3M

AI Insight: VYNE Financial Trends

Cash burn rate halved to $4M quarterly in Q1 2026, but equity base eroded 70% since Q1 2024 as company remains pre-revenue.

• Operating losses narrowed sharply: from $13M in Q3–Q4 2024 to $4M in Q1 2026, signaling cost discipline.

• Operating cash burn also tightened to $4M in Q1 2026 from $9–11M in prior quarters.

• Equity fell 70% from $83M (Q1 2024) to $25M (Q1 2026) with zero debt, indicating runway constraints.

⚠ Company remains pre-revenue across all periods; cost cuts have slowed burn but cannot sustainably replace product sales.

⚠ At current $4M quarterly burn, ~6 quarters of equity runway remain without external capital or revenue inflection.

AI Insight: VYNE Ratio Trends

VYNE remains deeply unprofitable with ROIC at -62.0% in Q1 2026, though severity has moderated from Q4 2024's -98.1% trough.

• ROIC improved 36.1pp from Q4 2024 (-98.1%) to Q1 2026 (-62.0%), signaling reduced quarterly cash burn.

• ROA deteriorated from -51.5% in Q2 2025 to -55.4% in Q1 2026, reversing prior recovery momentum.

⚠ All profitability metrics remain negative; no operating margin or net profit data visible across the series.

⚠ Q4 2025 missing from table; Q1 2026 ROA rebound needs confirmation—may reflect seasonal timing rather than operational improvement.

Get alerted when VYNE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for VYNE Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VYNE

Nantahala Capital Management, LLC
$1.2M2,000,000 sh
Lynx1 Capital Management LP
$973.1K1,628,700 sh
Shay Capital LLC
$962.1K1,610,242 sh
Anson Funds Management LP
$742.8K1,243,106 sh
ADAR1 Capital Management, LLC
$635.7K1,063,899 sh
T3 Companies, LLC
$564.6K945,000 sh
BRAIDWELL LP
$547.4K916,077 sh
CITADEL ADVISORS LLC
$307.4K514,443 sh
KVP Capital Advisors, LP
$299.1K500,551 sh
TWO SIGMA INVESTMENTS, LP
$254.8K426,412 sh

Fund	Value	Shares
Nantahala Capital Management, LLC	$1.2M	2,000,000
Lynx1 Capital Management LP	$973.1K	1,628,700
Shay Capital LLC	$962.1K	1,610,242
Anson Funds Management LP	$742.8K	1,243,106
ADAR1 Capital Management, LLC	$635.7K	1,063,899
T3 Companies, LLC	$564.6K	945,000
BRAIDWELL LP	$547.4K	916,077
CITADEL ADVISORS LLC	$307.4K	514,443
KVP Capital Advisors, LP	$299.1K	500,551
TWO SIGMA INVESTMENTS, LP	$254.8K	426,412

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VYNE on your watchlist

Track score changes the day VYNE Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VYNE a good stock to buy?

13F Pro's AI-powered analysis of VYNE Therapeutics Inc. (VYNE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VYNE are available on the VYNE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VYNE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VYNE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of VYNE Therapeutics Inc.'s investment landscape.